Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.